Table 1.
Characteristics of ALK protein concentrations (by SRM), ALK sequencing results, ALK FISH, and ALK IHC in 18 non–small cell lung cancer FFPE tissues.
| Sample ID | Tumor histology | Mean ALK SRM protein concentration,amol/3g (SD) | ALK sequencing | ALK FISH | ALK IHC | Crizotinib treatment | Overall patient response |
|---|---|---|---|---|---|---|---|
| Dartmouth Medical Center | |||||||
| DH1 | ADCa | 153.9 (13.5) | WT | Positive | Positive | Yes | PFS 7 months; NED in spring 2012; lost to follow-up |
| DH2 | ADC | 261.0 (26.3) | NA | Positive | Positive | Yes | PFS 14 months; then NED |
| DH3 | ADC | 223.3b | NA | Positive | Positive | Yes | PFS 22 months; then NED; possibly independent of crizotinib because patient was on crizotinib only 5 months |
| DH4 | ADC (LN) | 453.0 (28.1) | WT | Positive | Positive | Yes | PFS 12 months; then AWD |
| DH5c | ADSCC | 216.4b | NA | Positive | Positive | No | Alive, NED |
| DH6c | ADSCC (LN) | 126.3 (12.7) | WT | Positive | Positive | No | Alive, NED |
| DH7 | ADSCC | ND | WT | Negative | Negative | No | |
| DH8 | ADC (brain) | ND | WT | Negative | Negative | No | |
| DH9 | ADC | ND | HT G->A | Positive | Negative | Yes | PD; then DOD |
| DH10 | ADC | ND | WT | Negative | Negative | No | |
| DH11 | ADC | ND | WT | Negative | Negative | No | |
| DH12 | ADC (brain) | ND | WT | Positive | Positive | Yes | PR of liver metastases for 10 months; then DOD |
| Cleveland Clinic | |||||||
| ALK002 | ADC | 336.6 (2.5) | WT | Positive | Positive | Yes | PFS 29 months; initial PR, then CR and currently NED |
| ALK081 | ADC | 138.8 (20.7) | WT | Positive | Positive | No | Alive |
| ALK083 | ADC | 153.9 (12.9) | WT | Positive | Positive | No | Alive |
| ALK516 | ADC | 106.4 (6.4) | WT | Positive | Positive | No | Alive, NED |
| ALK634 | ADC | 136.3 (24.6) | WT | Positive | Positive | No | OS 14 months; DOD |
| West Virginia University | |||||||
| CD0370 | ADC | ND | NA | Positive | NA | Yes | PFS <2 months; DOD |
a
ADC, adenocarcinoma; WT, wild type; PFS, progression-free survival; NED, no evidence of disease; NA, not available; LN, lymph node; AWD, alive with disease; ADSCC, adenosquamous cell carcinoma; HT G->A, heterozygous G->A point mutation on DNA region encoding for the mass-spectrometry-targeted peptide; ND, not detected; PD, progressive disease; DOD, died of disease; PR, partial response; CR, complete response; OS, overall survival.
b
Measurements in DH3 and DH5 were from a single SRM analysis.
c
Samples DH5 and DH6 are from the same patient.